Amyloidosis is a rare protein-related condition that occurs when your body produces too many amyloid proteins, causing damage to your organs and tissues. Amyloid proteins are a type of protein ...

The most common nonfamilial forms of amyloidosis that involve the kidney are the AL (amyloid light chain) and AA (serum amyloid A) types. These two forms require different treatment strategies ...

Several case reports and retrospective cohort studies have described a marginal benefit with the use of internal cardioverter defibrillators in patients with cardiac amyloidosis. Detection of ...

AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of a couple of months.

Hereditary ATTR amyloidosis (hATTR amyloidosis) is a rare, debilitating disease that runs in families. It's caused by ...

Transthyretin amyloidosis is a progressive, fatal disease that often leads to cardiomyopathy. New research findings on vutrisiran for patients with transthyretin amyloidosis with cardiomyopathy ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

"The methodologies we've developed have opened new doors to avenues of treatment that could one day protect patients from not just TTR amyloidosis, but other amyloid diseases as well," says Lander.

Amvuttra (vutrisiran) is a follow-up to Alnylam's earlier RNA interference (RNAi) ATTR amyloidosis therapy Onpattro (patisiran), which was cleared by NICE for NHS use in 2019, but offers a simpler ...

Considering taking supplements to treat amyloidosis? Below is a list of common natural remedies used to treat or reduce the symptoms of amyloidosis. Follow the links to read common uses ...

Successfully dosed 6 patients in safety run-in segment, now accelerating enrollment Positive data from first four patients announced December 2024 NXC-201 is the only one-time CAR-T therapy in ...